The binding energy of SGLT1 and SGLT2 inhibitors is important for determining the efficacy of therapeutic agents by measuring how strongly a compound binds to the SGLT protein, and ultimately designing novel SGLT inhibitors for conditions like diabetes. Here, SLC5A2 is linked to diabetes mellitus.